Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia

Schizophrenia Research

Volumn 164, Issue 1-3, 2015, Pages 164-175

  Nakajima, Shinichiro ^a,b,c   Takeuchi, Hiroyoshi ^a,b,c   Plitman, Eric ^a,d   Fervaha, Gagan ^a,d   Gerretsen, Philip ^a,b,d   Caravaggio, Fernando ^a,d   Chung, Jun Ku ^a,d   Iwata, Yusuke ^a,b,c   Remington, Gary ^a,b   Graff Guerrero, Ariel ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clozapine; Glutamate; Neuroimaging; Schizophrenia; Treatment resistance

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

BASAL GANGLION; BRAIN METABOLISM; CENTRAL NERVOUS SYSTEM; COMPUTER ASSISTED TOMOGRAPHY; CORPUS CALLOSUM; DIFFUSION TENSOR IMAGING; DRUG EFFICACY; EMBASE; FRONTAL CORTEX; FUNCTIONAL NEUROIMAGING; GLUTAMATERGIC SYSTEM; HUMAN; MEDLINE; NERVE CELL NETWORK; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCINFO; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW; THALAMUS; TREATMENT RESISTANT SCHIZOPHRENIA; TREATMENT RESPONSE; DRUG RESISTANCE; NEUROIMAGING;

ANTIPSYCHOTIC AGENTS; DRUG RESISTANCE; HUMANS; NEUROIMAGING; SCHIZOPHRENIA;

EID: 84929281198     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.01.043     Document Type: Review

References (112)

1. Abbott C., Bustillo J. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update. Curr. Opin. Psychiatry 2006, 19(2):135-139.
2. Abdul-Monim Z., Reynolds G.P., Neill J.C. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav. Brain Res. 2006, 169(2):263-273.
3. Abekawa T., Ito K., Koyama T. Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex. Naunyn Schmiedebergs Arch. Pharmacol. 2006, 374(3):177-193.
4. Abekawa T., Ito K., Koyama T. Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the rat medial prefrontal cortex at short- and long-term withdrawal from this antipsychotic. Naunyn Schmiedebergs Arch. Pharmacol. 2007, 375(4):261-271.
5. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., van Dyck C.H., Charney D.S., Innis R.B., Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 1998, 155(6):761-767.
6. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., Weiss R., Cooper T.B., Mann J.J., Van Heertum R.L., Gorman J.M., Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(14):8104-8109.
7. Agid O., Arenovich T., Sajeev G., Zipursky R.B., Kapur S., Foussias G., Remington G. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J. Clin. Psychiatry 2011, 72(11):1439-1444.
8. Amitai N., Semenova S., Markou A. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology (Berl.) 2007, 193(4):521-537.
9. Amitai N., Kuczenski R., Behrens M.M., Markou A. Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats. Neuropharmacology 2012, 62(3):1422-1431.
10. Arango C., Breier A., McMahon R., Carpenter W.T., Buchanan R.W. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Am. J. Psychiatry 2003, 160(8):1421-1427.
11. Arnone D., Cavanagh J., Gerber D., Lawrie S.M., Ebmeier K.P., McIntosh A.M. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. Br. J. Psychiatry 2009, 195(3):194-201.
12. Breier A., Adler C.M., Weisenfeld N., Su T.P., Elman I., Picken L., Malhotra A.K., Pickar D. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 1998, 29(2):142-147.
13. Brugger S., Davis J.M., Leucht S., Stone J.M. Proton magnetic resonance spectroscopy and illness stage in schizophrenia-a systematic review and meta-analysis. Biol. Psychiatry 2011, 69(5):495-503.
14. Buchanan R.W., Breier A., Kirkpatrick B., Ball P., Carpenter W.T. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiatry 1998, 155(6):751-760.
15. Buchsbaum M.S., Haznedar M., Newmark R.E., Chu K.W., Dusi N., Entis J.J., Goldstein K.E., Goodman C.R., Gupta A., Hazlett E., Iannuzzi J., Torosjan Y., Zhang J., Wolkin A. FDG-PET and MRI imaging of the effects of sertindole and haloperidol in the prefrontal lobe in schizophrenia. Schizophr. Res. 2009, 114(1-3):161-171.
16. Cachia A., Paillere-Martinot M.L., Galinowski A., Januel D., de Beaurepaire R., Bellivier F., Artiges E., Andoh J., Bartres-Faz D., Duchesnay E., Riviere D., Plaze M., Mangin J.F., Martinot J.L. Cortical folding abnormalities in schizophrenia patients with resistant auditory hallucinations. NeuroImage 2008, 39(3):927-935.
17. Cadenhead K.S. Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population. Psychiatry Res. 2011, 188(2):208-216.
18. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci. 1990, 13(7):272-276.
19. Cepeda C., Levine M.S. Dopamine and N-methyl-d-aspartate receptor interactions in the neostriatum. Dev. Neurosci. 1998, 20(1):1-18.
20. Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 2001, 158(4):518-526.
21. Chung C., Remington G. Predictors and markers of clozapine response. Psychopharmacology (Berl.) 2005, 179(2):317-335.
22. Cipriani A., Boso M., Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst. Rev. 2009, 3:CD006324.
23. Conley R.R., Kelly D.L. Management of treatment resistance in schizophrenia. Biol. Psychiatry 2001, 50(11):898-911.
24. Conley R.R., Kelly D.L., Beason-Held L.L., Holcomb H.H., Richardson C.M. The effects of clozapine and high-dose olanzapine on brain function in treatment-resistant schizophrenia: a case study. J. Psychopharmacol. 2004, 18(3):429-431.
25. Coppens H.J., Slooff C.J., Paans A.M., Wiegman T., Vaalburg W., Korf J. High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol. Psychiatry 1991, 29(7):629-634.
26. David H.N., Ansseau M., Abraini J.H. Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of "intact" animals. Brain Res. Brain Res. Rev. 2005, 50(2):336-360.
27. Demjaha A., Murray R.M., McGuire P.K., Kapur S., Howes O.D. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am. J. Psychiatry. 2012, 169(11):1203-1210.
28. Demjaha A., Egerton A., Murray R.M., Kapur S., Howes O.D., Stone J.M., McGuire P.K. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol. Psychiatry 2014, 75(5):e11-e13.
29. Di Costanzo A., Trojsi F., Tosetti M., Giannatempo G.M., Nemore F., Piccirillo M., Bonavita S., Tedeschi G., Scarabino T. High-field proton MRS of human brain. Eur. J. Radiol. 2003, 48(2):146-153.
30. Di Costanzo A., Trojsi F., Tosetti M., Schirmer T., Lechner S.M., Popolizio T., Scarabino T. Proton MR spectroscopy of the brain at 3T: an update. Eur. Radiol. 2007, 17(7):1651-1662.
31. Didriksen M., Skarsfeldt T., Arnt J. Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics. Psychopharmacology (Berl.) 2007, 193(2):225-233.
32. Ebdrup B.H., Norbak H., Borgwardt S., Glenthoj B. Volumetric changes in the basal ganglia after antipsychotic monotherapy: a systematic review. Curr. Med. Chem. 2013, 20(3):438-447.
33. Ellison-Wright I., Glahn D.C., Laird A.R., Thelen S.M., Bullmore E. The anatomy of first-episode and chronic schizophrenia: an anatomical likelihood estimation meta-analysis. Am. J. Psychiatry 2008, 165(8):1015-1023.
34. Farooq S., Agid O., Foussias G., Remington G. Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification. Schizophr. Bull. 2013, 39(6):1169-1172.
35. Fitzgerald P.B., Sritharan A., Benitez J., Daskalakis Z.J., Jackson G., Kulkarni J., Egan G.F. A preliminary fMRI study of the effects on cortical activation of the treatment of refractory auditory hallucinations with rTMS. Psychiatry Res. 2007, 155(1):83-88.
36. Friedman L., Knutson L., Shurell M., Meltzer H.Y. Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol. Psychiatry 1991, 29(9):865-877.
37. Fusar-Poli P., Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11) C]-DOPA PET studies. Schizophr. Bull. 2013, 39(1):33-42.
38. Giesel F.L., Mehndiratta A., Hempel A., Hempel E., Kress K.R., Essig M., Schroder J. Improvement of auditory hallucinations and reduction of primary auditory area's activation following TMS. Eur. J. Radiol. 2012, 81(6):1273-1275.
39. Grace A.A. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res. Brain Res. Rev. 2000, 31(2-3):330-341.
40. Grayson B., Idris N.F., Neill J.C. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav. Brain Res. 2007, 184(1):31-38.
41. Hashimoto K., Fujita Y., Shimizu E., Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur. J. Pharmacol. 2005, 519(1-2):114-117.
42. Hietala J., Syvalahti E., Vilkman H., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., Solin O., Kuoppamaki M., Eronen E., Ruotsalainen U., Salokangas R.K. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr. Res. 1999, 35(1):41-50.
43. Holleran L., Ahmed M., Anderson-Schmidt H., McFarland J., Emsell L., Leemans A., Scanlon C., Dockery P., McCarthy P., Barker G.J., McDonald C., Cannon D.M. Altered interhemispheric and temporal lobe white matter microstructural organization in severe chronic schizophrenia. Neuropsychopharmacology 2014, 39(4):944-954.
44. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 2009, 35(3):549-562.
45. Howes O.D., Montgomery A.J., Asselin M.C., Murray R.M., Grasby P.M., McGuire P.K. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br. J. Psychiatry Suppl. 2007, 51:s13-s18.
46. Howes O.D., Egerton A., Allan V., McGuire P., Stokes P., Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr. Pharm. Des. 2009, 15(22):2550-2559.
47. Howes O.D., Kambeitz J., Kim E., Stahl D., Slifstein M., Abi-Dargham A., Kapur S. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch. Gen. Psychiatry 2012, 69(8):776-786.
48. Idris N.F., Repeto P., Neill J.C., Large C.H. Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and d-amphetamine in the rat. Psychopharmacology (Berl.) 2005, 179(2):336-348.
49. Jardri R., Delevoye-Turrell Y., Lucas B., Pins D., Bulot V., Delmaire C., Thomas P., Delion P., Goeb J.L. Clinical practice of rTMS reveals a functional dissociation between agency and hallucinations in schizophrenia. Neuropsychologia 2009, 47(1):132-138.
50. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148(10):1301-1308.
51. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45(9):789-796.
52. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 2003, 160(1):13-23.
53. Kapur S., Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am. J. Psychiatry 2001, 158(3):360-369.
54. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 2000, 157(4):514-520.
55. Kegeles L.S., Abi-Dargham A., Zea-Ponce Y., Rodenhiser-Hill J., Mann J.J., Van Heertum R.L., Cooper T.B., Carlsson A., Laruelle M. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol. Psychiatry 2000, 48(7):627-640.
56. Klirova M., Horacek J., Novak T., Cermak J., Spaniel F., Skrdlantova L., Mohr P., Hoschl C. Individualized rTMS neuronavigated according to regional brain metabolism ((18)FGD PET) has better treatment effects on auditory hallucinations than standard positioning of rTMS: a double-blind, sham-controlled study. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263(6):475-484.
57. Konicki P.E., Kwon K.Y., Steele V., White J., Fuller M., Jurjus G.J., Jaskiw G.E. Prefrontal cortical sulcal widening associated with poor treatment response to clozapine. Schizophr. Res. 2001, 48(2-3):173-176.
58. Krystal J.H. Capitalizing on extrasynaptic glutamate neurotransmission to treat antipsychotic-resistant symptoms in schizophrenia. Biol. Psychiatry 2008, 64(5):358-360.
59. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51(3):199-214.
60. Kubera K.M., Sambataro F., Vasic N., Wolf N.D., Frasch K., Hirjak D., Thomann P.A., Wolf R.C. Source-based morphometry of gray matter volume in patients with schizophrenia who have persistent auditory verbal hallucinations. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 50:102-109.
61. Kulagina N.V., Zigmond M.J., Michael A.C. Glutamate regulates the spontaneous and evoked release of dopamine in the rat striatum. Neuroscience 2001, 102(1):121-128.
62. Kuroki T., Nagao N., Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog. Brain Res. 2008, 172:199-212.
63. Langguth B., Eichhammer P., Zowe M., Marienhagen J., Spiessl H., Hajak G. Neuronavigated transcranial magnetic stimulation and auditory hallucinations in a schizophrenic patient: monitoring of neurobiological effects. Schizophr. Res. 2006, 84(1):185-186.
64. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(17):9235-9240.
65. Leung M., Cheung C., Yu K., Yip B., Sham P., Li Q., Chua S., McAlonan G. Gray matter in first-episode schizophrenia before and after antipsychotic drug treatment. Anatomical likelihood estimation meta-analyses with sample size weighting. Schizophr. Bull. 2011, 37(1):199-211.
66. Levine M.S., Cepeda C. Dopamine modulation of responses mediated by excitatory amino acids in the neostriatum. Adv. Pharmacol. 1998, 42:724-729.
67. Liao Z.L., Hu S.H., Xu Y. A case report on the relationship between treatment-resistant childhood-onset schizophrenia and an abnormally enlarged cavum septum pellucidum combined with cavum vergae. Chin. Med. J. (Engl.) 2012, 125(7):1349-1351.
68. Lieberman J.A., Safferman A.Z., Pollack S., Szymanski S., Johns C., Howard A., Kronig M., Bookstein P., Kane J.M. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am. J. Psychiatry 1994, 151(12):1744-1752.
69. Lieberman J.A., Bymaster F.P., Meltzer H.Y., Deutch A.Y., Duncan G.E., Marx C.E., Aprille J.R., Dwyer D.S., Li X.M., Mahadik S.P., Duman R.S., Porter J.H., Modica-Napolitano J.S., Newton S.S., Csernansky J.G. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol. Rev. 2008, 60(3):358-403.
70. Lindenmayer J.P. Treatment refractory schizophrenia. Psychiatr. Q. 2000, 71(4):373-384.
71. Lopez-Gil X., Babot Z., Amargos-Bosch M., Sunol C., Artigas F., Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2007, 32(10):2087-2097.
72. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996, 14(5):301-307.
73. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997, 17(3):141-150.
74. Mamo D., Graff A., Mizrahi R., Shammi C.M., Romeyer F., Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am. J. Psychiatry 2007, 164(9):1411-1417.
75. Marsman A., van den Heuvel M.P., Klomp D.W., Kahn R.S., Luijten P.R., Hulshoff Pol H.E. Glutamate in schizophrenia: a focused review and meta-analysis of (1)H-MRS studies. Schizophr. Bull. 2013, 39(1):120-129.
76. Meltzer H.Y., Burnett S., Bastani B., Ramirez L.F. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp. Community Psychiatry 1990, 41(8):892-897.
77. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:b2535.
78. Molina Rodriguez V., Montz Andree R., Perez Castejon M.J., Capdevila Garcia E., Carreras Delgado J.L., Rubia Vila F.J. SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine. Am. J. Psychiatry 1996, 153(10):1343-1346.
79. Molina Rodriguez V., Andree R.M., Castejon M.J., Zamora M.L., Alvaro P.C., Delgado J.L., Vila F.J. Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients. A 99mTc-HMPAO study. Psychiatry Res. 1997, 76(1):51-61.
80. Molina Rodriguez V., Montz Andree R., Perez Castejon M.J., Gutierrez Labrador R., Ferre Navarrete F., Carreas Delgado J.L., Rubia Vila F.J. Cerebral perfusion correlates of negative symptomatology and parkinsonism in a sample of treatment-refractory schizophrenics: an exploratory 99mTc-HMPAO SPET study. Schizophr. Res. 1997, 25(1):11-20.
81. Molina Rodriguez V., Reig S., Sarramea F., Sanz J., Francisco Artaloytia J., Luque R., Aragues M., Pascau J., Benito C., Palomo T., Desco M. Anatomical and functional brain variables associated with clozapine response in treatment-resistant schizophrenia. Psychiatry Res. 2003, 124(3):153-161.
82. Molina Rodriguez V., Gispert J.D., Reig S., Sanz J., Pascau J., Santos A., Desco M., Palomo T. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. Psychopharmacology (Berl.) 2005, 178(1):17-26.
83. Molina Rodriguez V., Sanz J., Sarramea F., Palomo T. Marked hypofrontality in clozapine-responsive patients. Pharmacopsychiatry 2007, 40(4):157-162.
84. Molina Rodriguez V., Tamayo P., Montes C., De Luxan A., Martin C., Rivas N., Sancho C., Dominguez-Gil A. Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(4):948-954.
85. Nord M., Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci. Ther. 2011, 17(2):97-103.
86. Nordstrom A.L., Farde L., Nyberg S., Karlsson P., Halldin C., Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am. J. Psychiatry 1995, 152(10):1444-1449.
87. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52(12):998-1007.
88. Remington G., Kapur S., Foussias G., Agid O., Mann S., Borlido C., Richards S., Javaid N. Tetrabenazine augmentation in treatment-resistant schizophrenia: a 12-week, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2012, 32(1):95-99.
89. Roberts R.C., Roche J.K., Conley R.R., Lahti A.C. Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response. Synapse 2009, 63(6):520-530.
90. Samaha A.N., Reckless G.E., Seeman P., Diwan M., Nobrega J.N., Kapur S. Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol. Psychiatry 2008, 64(2):145-152.
91. Sato M., Numachi Y., Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr. Bull. 1992, 18(1):115-122.
92. Schreiber S., Dannon P.N., Goshen E., Amiaz R., Zwas T.S., Grunhaus L. Right prefrontal rTMS treatment for refractory auditory command hallucinations-a neuroSPECT assisted case study. Psychiatry Res. 2002, 116(1-2):113-117.
93. Seeman P., Kapur S. Schizophrenia: more dopamine, more D2 receptors. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(14):7673-7675.
94. Selvaraj S., Arnone D., Cappai A., Howes O. Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci. Biobehav. Rev. 2014, 45:233-245.
95. Sharp F.R., Tomitaka M., Bernaudin M., Tomitaka S. Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia?. Trends Neurosci. 2001, 24(6):330-334.
96. Sommer I.E., Begemann M.J., Temmerman A., Leucht S. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr. Bull. 2012, 38(5):1003-1011.
97. Steen R.G., Mull C., McClure R., Hamer R.M., Lieberman J.A. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br. J. Psychiatry 2006, 188:510-518.
98. Sun J., Maller J.J., Daskalakis Z.J., Furtado C.C., Fitzgerald P.B. Morphology of the corpus callosum in treatment-resistant schizophrenia and major depression. Acta Psychiatr. Scand. 2009, 120(4):265-273.
99. Suzuki T., Uchida H., Watanabe K., Kashima H. Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacol. Bull. 2011, 44(1):32-60.
100. Suzuki T., Remington G., Mulsant B.H., Uchida H., Rajji T.K., Graff-Guerrero A., Mimura M., Mamo D.C. Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012, 197(1-2):1-6.
101. Tauscher J., Kufferle B., Asenbaum S., Fischer P., Pezawas L., Barnas C., Tauscher-Wisniewski S., Brucke T., Kasper S. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology (Berl.) 1999, 141(2):175-181.
102. Tauscher J., Hussain T., Agid O., Verhoeff N.P., Wilson A.A., Houle S., Remington G., Zipursky R.B., Kapur S. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am. J. Psychiatry 2004, 161(9):1620-1625.
103. Uchida H., Takeuchi H., Graff-Guerrero A., Suzuki T., Watanabe K., Mamo D.C. Predicting dopamine D(2) receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J. Clin. Psychopharmacol. 2011, 31(3):318-325.
104. Vercammen A., Knegtering H., Liemburg E.J., den Boer J.A., Aleman A. Functional connectivity of the temporo-parietal region in schizophrenia: effects of rTMS treatment of auditory hallucinations. J. Psychiatr. Res. 2010, 44(11):725-731.
105. West A.R., Floresco S.B., Charara A., Rosenkranz J.A., Grace A.A. Electrophysiological interactions between striatal glutamatergic and dopaminergic systems. Ann. N. Y. Acad. Sci. 2003, 1003:53-74.
106. Wolf N.D., Sambataro F., Vasic N., Frasch K., Schmid M., Schonfeldt-Lecuona C., Thomann P.A., Wolf R.C. Dysconnectivity of multiple resting-state networks in patients with schizophrenia who have persistent auditory verbal hallucinations. J. Psychiatry Neurosci. 2011, 36(6):366-374.
107. Wolf N.D., Gron G., Sambataro F., Vasic N., Frasch K., Schmid M., Thomann P.A., Wolf R.C. Magnetic resonance perfusion imaging of auditory verbal hallucinations in patients with schizophrenia. Schizophr. Res. 2012, 134(2-3):285-287.
108. Yamamoto H., Kitamura N., Lin X.H., Ikeuchi Y., Hashimoto T., Shirakawa O., Maeda K. Differential changes in glutamatergic transmission via N-methyl-d-aspartate receptors in the hippocampus and striatum of rats behaviourally sensitized to methamphetamine. Int. J. Neuropsychopharmacol. 1999, 2(3):155-163.
109. Yao L., Lui S., Liao Y., Du M.Y., Hu N., Thomas J.A., Gong Q.Y. White matter deficits in first episode schizophrenia: an activation likelihood estimation meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 45:100-106.
110. Yilmaz Z., Zai C.C., Hwang R., Mann S., Arenovich T., Remington G., Daskalakis Z.J. Antipsychotics, dopamine D(2) receptor occupancy and clinical improvement in schizophrenia: A meta-analysis. Schizophr. Res. 2012, 140(1-3):214-220.
111. Yoshimura R., Ueda N., Shinkai K., Nakamura J. Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. Int. Clin. Psychopharmacol. 2003, 18(2):107-111.
112. Zugman A., Gadelha A., Assuncao I., Sato J., Ota V.K., Rocha D.L., Mari J.J., Belangero S.I., Bressan R.A., Brietzke E., Jackowski A.P. Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia. Schizophr. Res. 2013, 148(1-3):81-86.